Log In
Print this Print this

Anti-CD19 antibody-drug conjugate, MDX-1342

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionAntibody targeting CD19
Molecular Target CD19
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsTreat chronic lymphocytic leukemia (CLL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today